Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the completion of a clinical study in support of the Xibrom QD NDA, the resubmission of the clinical section of the Xibrom QD NDA, the launch of Xibrom QD prior to the expiration of the twice-daily patent, the goals to continue to build sales, establish new physician relationships, and complete the Bepreve clinical studies in order to submit the NDA in 2008, 2008 financial guidance and ISTA's goals of reaching profitability in 2009 and beyond, bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency a
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... SAN FRANCISCO , Sept. 17, 2014 /PRNewswire/ ... patients receiving accelerated partial breast irradiation (APBI) via ... and those with positive lymph nodes could be ... for Radiation Oncology (ASTRO) guidelines place these patients ... an abstract at the 2014 ASTRO meeting, Beaumont ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... Sept. 26 MacroGenics, Inc. announced,today that Mr. ... of the,company,s Board of Directors. With more than ... in the pharmaceutical and,biotechnology industry, Mr. Buchalter is ... MacroGenics as the company matures toward,commercializing its pipeline. ...
... XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: ... 2007, the Company received a NASDAQ Staff,Determination indicating ... minimum,$10 million shareholders, equity requirement for continued listing ... Marketplace Rule 4450(a)(3), and that,its ADRs are, therefore, ...
... Empowers Life Sciences Community with accelerated BioInformatics, ... Corp., announced,the initiation of Progeniq Pte Ltd, ... Singapore, into the BioIT Alliance today. The,BioIT ... integrate science and,technology to accelerate the pace ...
Cached Biology Technology:Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... atmospheric scientists were instrumental in the creation of the ... to classify the fire threat potential of the powerful, ... spark into an inferno. The index was introduced Sept. ... UCLA and San Diego Gas and Electric. , The ... "extreme" that will be used to help fire agencies ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... Research led by T. Cooper Woods, PhD, Assistant Professor ... Center New Orleans, and Director of the Molecular Cardiology ... mechanism of how a drug commonly used on stents ... movement which is critical to wound healing and the ...
... TORONTO (April 13, 2010) -- An investigational intervention using ... thinking abilities of a group of mild- to moderate-stage ... rate of atrophy (shrinkage) of their brains, according to ... Center. These and other findings from the Phase II ...
... the Department of Computer Science at Virginia Tech have used ... by scientists in their quest to define the microbial DNA ... computers from across the world, the mpiBLAST computational tool used ... 90 years it would have required if the work were ...
Cached Biology News:Research discovery may lead to advances in heart disease and cancer treatment 2Investigational immune intervention slows brain shrinkage in Alzheimer's patients 2Investigational immune intervention slows brain shrinkage in Alzheimer's patients 3Investigational immune intervention slows brain shrinkage in Alzheimer's patients 4High-performance computing reveals missing genes 2High-performance computing reveals missing genes 3
...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... PCR detection system holds 48 x 0.2 ml ... 48 LEDs independently excites fluorescence (470-500 nm) for ... detects emitted light (523-543 nm and 540-700 nm). ... cycler, whose Peltier heat pumps provide superb thermal ...
Biology Products: